DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Olivia Brayer - 4 Cantor Fitzgerald - 3 Amgen - 2 Eli Lilly - 2 Morgan Stanley - 2 Eli - 1 Wegovy - 1 Brayer - 1
Top related locs:
Nordisk — U.S Danish Las Vegas Bristol Generac Europe CSIQ —
Top related orgs:
Novo Nordisk - 2 Food and Drug Administration - 2 JPMorgan - 2 Bank of America - 2 CNBC - 2 BMO - 1 Bristol Myers Squibb - 1 Bristol - 1

Search resuls for: "Brayer"


4 mentions found


☆ Amgen stock falls as analysts mull over weight loss drug’s bone density data
  + stars: | 2024-11-12 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. Amgen did not immediately respond to a request for comment on the dataThe drug is a promising potential competitor in the weight loss drug market. "On one hand, patients could naturally lose bone mineral density during weight loss treatment," Brayer wrote. But Brayer said, "on the other hand, this could be a non-starter because there seems to be a dose-dependent increase" in bone mineral density loss. Amgen is also aware of the "hypothetical concern" of bone mineral density loss, Yee said, citing the firm's discussions with management.
Persons: Amgen, Eli Lilly, Cantor Fitzgerald, Olivia Brayer, Eli, Wegovy, Brayer, Jefferies, Michael Yee, Yee, Evan Seigerman, hasn't, Seigerman Organizations: Novo Nordisk, BMO
☆ Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
  + stars: | 2024-09-27 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +3 min
That came after short-seller Hindenburg Research revealed last month it had taken a short position in the company, citing "fresh evidence of accounting manipulation." Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley. Amgen — The biotech's shares rose 2% after Cantor Fitzgerald initiated research coverage with an overweight rating. — The aerospace and defense stock added 16% following a price target increase from KeyBanc Capital Markets, which retained an overweight investment rating.
Persons: Bristol Myers, Hindenburg, Morgan Stanley, Amgen, Cantor Fitzgerald, Olivia Brayer, Michael Leshock, — CNBC's Sean Conlon, Alex Harring, Yun Li, Hakyung Kim, Samantha Subin, Pia Singh Organizations: Bristol Myers Squibb, Food and Drug Administration, Bristol, Nordisk —, JPMorgan, Wall, Costco Wholesale, Revenue, Wall Street Journal, Justice Department, Hindenburg Research, Securities and Exchange Commission, Wynn Resorts, UAE, HP Inc, Bank of America, KeyBanc Locations: Nordisk — U.S, Danish, Las Vegas
☆ Wednesday's analyst calls: DraftKings bull case, credit card play for the long haul
  + stars: | 2023-11-15 | by ( Brian Evans Fred Imbert | Brian Evans | Fred Imbert | ) www.cnbc.com   time to read: +7 min
Wednesday's batch of analyst research included bullish calls on a credit card giant and a sports betting name. The firm downgraded the pharmaceutical stock to neutral from overweight and lowered its price target to $55 per share from $68. The bank downgraded the Canadian Solar to underweight from neutral in a Wednesday note and lowered its price target to $22 per share from $32. The analyst noted that the guidance given confirms his bull case for the stock, which consists of a $70 price target. The bank initiated coverage of the credit card giant with an overweight rating and a $184 per share price target — which implies more than 17% upside from Tuesday's close.
Persons: Morgan Stanley, Guggenheim, John DiFucci, there's, Brian Evans, Cantor Fitzgerald downgrades, Myers Squibb Cantor Fitzgerald, We've, Olivia Brayer, Myers Squibb, — Brian Evans, Julien Dumoulin, Smith, Wells, Omar Mejias, Mark Strouse, DraftKings, Stephen Grambling, Grambling, Fred Imbert, millennials, Z, Gen, Terry Ma Organizations: CNBC, Barclays, American Express, Guggenheim, FactSet, Myers Squibb, Bank of America, Wells Fargo, Warner Music Group, accel, JPMorgan, American Locations: Bristol, Generac, Europe, CSIQ
☆ 'Robot pills' could one day help patients avoid needles. The stocks are cheap, but risky
  + stars: | 2023-09-03 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +7 min
That's where a number of early-stage drug delivery companies come in — and most are flying under investors' radar. Drug delivery tends to be a "roll-up sector," explained Edward Nash, an analyst at Canaccord Genuity. Nash recently looked at four companies operating in drug delivery: Rani Therapeutics , Biora Therapeutics , Avalyn Pharma and Elektrofi. At the moment, the most effective GLP-1 medications for weight loss are delivered via a subcutaneous injection. The verstility of the Rani pill also is encouraging, according to Harrison, since it could be used with a wide range of drugs.
Persons: that's, Edward Nash, Nash, Rani, FactSet, Talat Imran, Eli Lilly, Evercore, Lilly, Genuity's Nash, Julian Harrison, Rani's, Harrison, Cantor Fitzgerald, Olivia Brayer, Imran, We're Organizations: Big Pharma, Therapeutics, Biora Therapeutics, Avalyn Pharma, CNBC, Novo Nordisk, Novo, European Union, Food and Drug Administration, Celltrion Locations: —
0 next >>
Total: 4